NEOS Investment Management LLC Has $30.73 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

NEOS Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,295 shares of the medical research company’s stock after buying an additional 6,304 shares during the quarter. NEOS Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $30,731,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Bank OZK bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $1,096,000. Ausdal Financial Partners Inc. purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth about $456,000. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $7,505,000. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. Finally, German American Bancorp Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $4,920,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TMO shares. CLSA assumed coverage on Thermo Fisher Scientific in a research report on Thursday. They issued an “outperform” rating and a C$748.00 target price for the company. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $612.75 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market cap of $226.56 billion, a PE ratio of 32.96, a price-to-earnings-growth ratio of 2.59 and a beta of 0.85. The stock has a 50-day moving average price of $570.91 and a 200-day moving average price of $515.10.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at $13,927,815. The trade was a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.